Safety, Efficacy, Efficiency & Quality: Scaling Your Continuous Processing from Technology to Commercial Manufacturing

Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology, both pharma and biotech are starting to adopt CM in commercial setting.

Over the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK, GSK’s announcement of CM facilities in Singapore, Fujiflim investing $10m in continuous bioprocessing technology, Merck has filed an NDA under CM approach, Bill & Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing.

Coming to the 4th annual CCP Summit, we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.

This is the one and only CCP meeting bringing together small molecules and biologics experts under one roof for knowledge and experience exchange! Returning to Boston for the 4th time on Jan 28 – 30, 2020 – register your interest now and be the first to receive information from us.